Participating Faculty: Translating Clinical Guidelines Into Practice: The Effective and Appropriate Use of Human Growth Hormone

Novo Nordisk

This supplement to The American Journal of Managed Care discusses how managed care policies and clinical guidelines on appropriate use of recombinant human growth hormone (rhGH) translate into real-world practice. Also discussed are the efficacy and safety of rhGH therapy for its pediatric indications, and the role of specialty pharmacies in managing patient access to therapy. The content of this supplement is based on a review of scientific literature and discussions from an expert roundtable panel consisting of clinicians and managed care professionals.Funding for the development of this supplement was provided by ; the opinions expressed are those of the authors and not necessarily those of Novo Nordisk.

Moderator

Robert P. Navarro, PharmD

Clinical Professor, Department of Pharmaceutical Outcomes & Policy

University of Florida College of Pharmacy

Gainesville, Florida

Faculty

Jeffrey D. Dunn, PharmD, MBA

Senior Vice President

VRx

Salt Lake City, Utah

Peter A. Lee, MD, PhD

Division of Pediatric Endocrinology

Department of Pediatrics

Hershey Medical Center

Hershey, Pennsylvania

Professor

Department of Pediatrics

Penn State College of Medicine

Hershey, Pennsylvania

Gary M. Owens, MD

President

Gary Owens Associates

Ocean View, Delaware

Robert Rapaport, MD

Professor of Pediatrics

Emma Elizabeth Sullivan Professor of Pediatric Endocrinology and Diabetes

Director

Division of Pediatric Endocrinology and Diabetes

Icahn School of Medicine at Mount Sinai/Kravis Children’s Hospital

New York, New York

Faculty Disclosures

These participants report relationships with the following organizations:

Peter A. Lee, MD, PhD

Board membership: Pediatric Endocrine Society

Consultant/advisory board member/honoraria: Novo Nordisk

Speaker: AbbVie

Robert Navarro, PharmD

Consultant: Astra-Zeneca, Forest, Ironwood, Novo Nordisk, Pfizer

Gary M. Owens, MD

Consultant/paid advisory board member: Eli Lilly and Company; Pfizer; Teva

Robert Rapaport, MD

Consultant/paid advisory board member: EMD Serono, Inc; Novo Nordisk; Sandoz

Jeffrey D. Dunn, PharmD, MBA, reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Download PDF: Participating Faculty: Translating Clinical Guidelines Into Practice: The Effective and Appropriate Use of Human Growth Hormone